MHRA: Special Mail 5: Frequently Asked Questions (version 2.1 - June 2009)

The guidance in Special MAIL 5 includes that for submitting new MA applications, MA variations and Clinical Trial applications. For MA applications and variations, it is expected that this guidance will remain in place until companies move to providing these submissions using the eCTD standard.